Public Comments to Agencies | Citizens Against Government Waste

Public Comments to Agencies

Agency Comments

CAGW Submits Comments to FDIC on Change in Bank Control Act

The proposed rulemaking would place undue burdens on investors and asset managers. 

Eric Maus November 18, 2024
Agency Comments

CAGW Submits Comments to FCC on Cell Phone Unlocking

The FCC's rulemaking is unnecessary and an example of regulatory overreach.

Eric Maus November 12, 2024
Agency Comments

CAGW Submits Comments on FTC's Interim Staff Report on PBMs

Overregulating PBMs will drive up prescription drug costs and be a disservice to the millions of patients that benefit from them.

Eric Maus August 1, 2024
Agency Comments

CAGW Submits Comments for Tobacco Products Scientific Advisory Committee Open Session

Efforts to reduce burn tobacco product use include less harmful alternatives to cigarettes. 

Eric Maus June 17, 2024
Agency Comments

CAGW Submits Ex Parte Presentation for April 10 meeting with Commissioner Gomez

 

Eric Maus May 1, 2024
Agency Comments

CAGW Files Comments with FCC on RDOF Emergency Petition

CAGW responds to an emergency petition filed by RDOF award winners asking for relief from the FCC's buildout requirements.

Eric Maus March 26, 2024
Agency Comments

CAGW Files Comments to the FCC On Proposed Net Neutrality Rulemaking

The re-classification of the internet as a Title II service will impose heavy-handed regulations and reduce broadband investments.

Eric Maus December 14, 2023
Agency Comments

CAGW Response to House Budget Committee and House Committee on Oversight and Accountability on Improper Payments

Congress should continue to conduct oversight to determine what further steps can be taken to reduce improper payments. 

Eric Maus September 27, 2023
Agency Comments

CAGW Files Comments on Federal Trade Commission and Department of Justice Draft Merger Guidance

The draft merger guidance will reduce competition and impose burdensome requirements on businesses across all industries. 

Eric Maus September 13, 2023
Agency Comments

CAGW Requests that the U.S. International Trade Commission Should not Expand the TRIPS Waiver

Expanding the COVID-19 TRIPS Wavier will further harm future biopharmaceutical research and development. 

Christina Smith May 4, 2023
Agency Comments

CAGW Submits Comments to CMS Against the Proposed Medicare Drug Price Negotiation Program Guidance

The proposed CMS guidance on enacting the IRA will harm patients by hindering drug research and development. 

Christina Smith April 14, 2023
Agency Comments

CAGW Response to Senator Thune on Broadband Funding

Broadband services should be properly implemented to prevent waste, fraud, abuse, and mismanagement. 

Eric Maus January 13, 2023

Pages